Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Diacrin

This article was originally published in The Gray Sheet

Executive Summary

Diacrin: Initial public offering of 2.5 mil. units at $8 per unit commences Feb. 13, the Charlestown, Massachusetts transplantable porcine cells developer announces. Each unit consists of one share of common stock and one warrant to purchase one share. At $8 per unit, the offering is priced below the $14 to $16 range projected by the company in its December SEC filing ("The Gray Sheet" Jan. 1, p. 24). The $20 mil. IPO is underwritten by PaineWebber and Vector Securities, which hold an option to purchase an additional 375,000 units to cover any over-allotments...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel